To investigate further transcripts targeted by branaplam we treated SH-SY5Y human neuroblastoma cells with 100 nM branaplam (5× higher dose than the EC50 for SMN agonism in vitro) for 24 h and confirmed transcript changes using RNA-seq (hereafter referred to as the first RNA-seq study). The gene discussed is SMN2; the disease is neuroblastoma.